Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. (United States) has no DMF, CEP or site registration linked in our records. 36 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Sagent Pharmaceuticals, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/sagent-pharmaceuticals-inc
Overview
Sagent Pharmaceuticals, Inc. is a leading developer, manufacturer, and marketer of pharmaceutical products with a focus on injectable drugs. As a subsidiary of Nichi-Iko Pharmaceutical Co., Ltd., Sagent emphasizes quality and innovation in producing essential medicines for healthcare providers.
Therapeutic areas
FDA compliance signals
36 FDA enforcement records linked to this company.
- recall — Class III2026-05-27
Failed Impurities/Degradation Specifications
- recall — Class I2024-06-19
Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.
- recall — Class I2024-06-19
Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.
- recall — Class II2024-05-22
Presence of Particulate Matter: Potential for black particulates in the drug product.
- recall — Class II2023-08-02
Lack of Assurance of Sterility
- recall — Class II2023-08-02
Lack of Assurance of Sterility
- recall — Class II2023-08-02
Lack of Assurance of Sterility
- recall — Class II2023-05-31
Lack of Assurance of Sterility
- recall — Class II2023-05-31
Lack of Assurance of Sterility
- recall — Class II2023-05-31
Lack of Assurance of Sterility
- recall — Class II2023-03-15
Labeling: Not elsewhere classified
- recall — Class II2021-03-24
Lack of Assurance of Sterility: customer complaints of loose crimped vial overseals which may result in a non-sterile product.
- 4832019-12-18
Contract drug products--lack of responsibility
- 4832019-12-18
Failure to meet specifications
- 4832019-12-18
SOPs not followed / documented
- 4832019-12-18
Authority lacking to review records, investigate errors
- 4832019-12-18
Contamination, chemical or physical change, deterioration
- 4832019-12-18
Inadequate number of personnel
- 4832019-12-18
Procedures not in writing, fully followed
- recall — Class II2019-05-15
Lack of Sterility Assurance: Microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.
- 4832018-09-24
Summary
- 4832018-09-24
Submission of report follow-up
- 4832018-09-24
Failure to develop written procedures
- 4832018-09-24
Late submission of 15-day report
- recall — Class II2018-03-21
Failed Impurities/Degradation Specifications: High out of specification results for an impurity.
- recall — Class II2018-03-21
Failed Impurities/Degradation Specifications: High out of specification results for an impurity.
- recall — Class II2018-03-21
Failed Impurities/Degradation Specifications: High out of specification results for an impurity.
- recall — Class II2016-08-03
Presence of Particulate Matter; The firm received two product complaints for small, dark particulate matter identified in solution post reconstitution.
- recall — Class II2016-03-30
Cross contamination with other products: metronidazole
- recall — Class II2015-03-11
Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic and GMP practices at the manufacturers site potentially impacting product sterility.
- recall — Class II2015-03-11
Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic and GMP practices at the manufacturers site potentially impacting product sterility.
- recall — Class II2014-10-22
Incorrect or Missing Lot and/or Exp Date: Ketorolac Tromethamine Injection, is being recalled as a result of labeling the product with the incorrect expiration date.
- recall — Class II2014-10-08
Lack of Assurance of Sterility; leaking of premix bags
- recall — Class II2013-06-26
CGMP Deviations: product was not manufactured under current good manufacturing practices which contributed to Failed Impurities/Degradation Specifications as a high out of specification impurity result was detected during routine quality testing of stability samples.
- 4832012-05-11
Failure to report non-alert ADEs
- 4832012-05-11
Failure to develop written procedures
Is this Sagent Pharmaceuticals, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.